Carisma Therapeutics announced that the first patient was dosed in its Phase 1 clinical trial evaluating CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor-monocyte cellular therapy, for the treatment of patients with solid tumors that overexpress human epidermal growth factor receptor 2.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Carisma Therapeutics price target lowered to $8 from $9 at H.C. Wainwright
- Securing Success: The Crucial Role of IP Rights in Carisma Therapeutics’ Market Dominance
- Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Carisma Therapeutics expects cash to fund operations into Q3 of 2025
- Carisma Therapeutics reports Q1 EPS (46c), consensus (43c)